In 2017, we identified more than 400 peer reviewed publications on the topic of pancreas transplantation, more than 500 on intestinal transplantation, more than 4000 on renal transplantation, and more than 4700 on liver transplantation. This annual review highlights the most pertinent literature for anesthesiologists and critical care physicians caring for patients undergoing abdominal organ transplantation. We explore a wide range of topics, including risk for and prediction of perioperative complications, recommendations on perioperative management, economic analyses, and education of the trainees in abdominal transplantation anesthesia and critical care.
Introduction
This annual review presents noteworthy publications regarding the perioperative care for adult patients undergoing abdominal organ transplantation: pancreas, intestine, renal, and liver. In this yearly update, in addition to focusing on several key articles pertinent to the anesthesiologist caring for patients undergoing abdominal organ transplantation, we also review highlights from the Organ Procurement and Transplantation Network/Scientific Registry of Transplant Recipients annual reports.
Pancreas Transplantation

Cardiovascular Outcomes
Patient and graft survival have steadily increased for all pancreas transplants both nationally and internationally. 1, 2 Simultaneous pancreas kidney transplant (SPK) graft and patient outcomes continue to improve, supporting combined transplant as a cure option for diabetic patients with concurrent kidney disease. 2 However, the 2015 Organ Procurement and Transplantation Network (OPTN)/ Scientific Registry of Transplant Recipients (SRTR) report highlights lower survival rates in type II diabetic patients after all types of pancreas transplant, likely secondary to this group's older age and comorbidities. 1 Kim et al 3 conducted a large, retrospective National Inpatient Sample study to evaluate perioperative cardiovascular complications after SPK, pancreas after kidney transplant (PAK), and pancreas transplant alone (PTA). 3 Kim's group reviewed cardiovascular complications, including acute myocardial infarction (MI), atrial fibrillation and flutter, congestive heart failure (CHF), and transient ischemic attack/stroke in 13 399 pancreas transplants between 2003 and 2012. Recipients who underwent SPK were younger and had more cardiovascular risk factors, including anemia, hypertension, and previous coronary revascularization. The overall rate of cardiovascular complications was 4.9% across all pancreas transplants. The authors demonstrated a significantly higher rate of stroke and CHF in SPK recipients compared with PAK/PTA recipients in univariate analysis. This association between SPK and cardiovascular complications remained significant in multivariate analysis (odds ratio [OR] = 1.48; P = .01); driven primarily by stroke (OR = 13.41; P = .001). In-hospital mortality was not statistically different between SPK and PAK/PTA recipients after multivariable adjustment. 3 Uremia is a well-known independent risk factor for stroke, 4, 5 and patients undergoing SPK are more likely to be uremic than patients undergoing PAK/PTA. These authors raise the question of whether patients with elevated risk of stroke would benefit from PAK over SPK and whether more resources should be directed to cardiovascular risk stratification and stroke prevention in patients with kidney disease and insulin-dependent diabetes. To appropriately answer these questions, prospective analyses are required. That said, this is the largest pooled analysis of cardiovascular complications in pancreas transplantation and may increase recognition of cardiovascular risk factors in this population.
OPTN/SRTR Pancreas Report
The 2015 OPTN/SRTR annual data report on pancreas transplantation represents the first full year of data following implementation of the new pancreas allocation system in October 2014. 1 This system merged all solid organ pancreas transplant types into a single waitlist. There was no change in distribution of PTA and SPK transplants and no decrease in PAK transplants. The body mass index limit was increased from 28 to 30 kg/m 2 with the goal of increasing the proportion of SPKs in type II diabetics; however, the percentage is still below 10%. A new initiative to improve utilization was accepted in December 2015, with procurement organizations able to facilitate allocation if no local offer had been accepted by 3 hours before procurement. Finally, the new pancreas graft failure definition was approved in 2015 and is awaiting implementation.
The number of active waitlist patients (994) has been stable since 2013. The new allocation system did not increase the percentage of type II diabetics on the waitlist. SPK and PTA listings increased, whereas PAK listings decreased. PAK candidates are less likely to undergo transplant. Overall waitlist mortality decreased in the last decade from 7.3 per 100 waitlist years in 2004 to 5.6 per 100 waitlist years in 2015. Transplant rates decreased slightly from a high of 77.8 transplants per 100 active waitlist years in 2013 to 71.5 transplants per 100 active waitlist years in 2015. The rate of transplants for type II diabetics increased over the prior decade, from 57.8 in 2004 to 90.1 in 2015; that said, the proportion of type II diabetic recipients did not increase from 2014 to 2015 with the new allocation system. A total of 947 pancreas transplants were performed in 2015, stable since 2013. Early graft failure has decreased over 10 years from 11.7% to 7.8%. Survival for PTA, SPK, and PAK, respectively, were as follows: 91.8%, 96.6%, and 100% at 1 year, and 78.2%, 89.6%, and 91.1% at 5 years. Those with type I diabetes had higher survival rates than those with type II diabetes (97.5% vs 93.9% at 1 year, 90% vs 86.4% at 5 years), likely secondary to the older age and comorbidities of those with type II diabetes.
Intestine Transplantation
Anesthetic Management
Before 2017, the anesthetic management of intestinal transplantation is described as being akin to the management of a liver transplant, including multiple large-bore central lines, a pulmonary artery catheter (PAC), rapid infusion system (RIS), 2 arterial lines, viscoelastic testing, and transesophageal echocardiography (TEE). 6 An update on anesthetic management for intestinal transplantation without transplantation of a hepatic graft was published this year by the Mount Sinai group describing 67 intestine, intestine-kidney, and intestine-pancreas transplants from 2005 to 2015. 7 All patients in this group were managed with a single radial arterial line; 61.2% had a single central line, 31.3% had 2 central lines, and 7.5% had no central line (but had at least 1 peripheral rapid infusion catheter). Patients with known difficult vascular access obtained central access by interventional radiologists prior to entry into the operating room, with 53% of patients entering the operating room with a central line already in place. Only 4.5% of cases utilized TEE, and only 1.5% used a PAC. Postreperfusion syndrome, defined as a greater than a 30% drop in mean arterial pressure, occurred in only 8.96% of cases within 5 minutes of reperfusion. Few patients required significant doses of potent vasoconstrictors/inotropes: norepinephrine (6%), epinephrine (1.5%), and vasopressin (3%). No patient experienced malignant arrhythmias or cardiac arrest. Although transfusion rates were high, with 83.6% of patients receiving red blood cells (RBCs), 31.3% plasma, and 23.9% platelets, the number of patients who received massive transfusion (MT) of >3000 mL of packed RBCs (pRBCs) was only 4.5%. Central Venous Pressure (CVP) was not utilized for fluid management, but systolic pressure variation and urine output with a goal of >0.5 mL/kg/h guided fluid management. Overall 30-day patient and graft survival were 94.03% and 86.57%, respectively. Owing to improved patient selection and surgical technique, when comparing 2005-2010 to 2011-2015, patient and graft 30-day survival improved to 97.4% and 89.3%, respectively.
The authors conclude that intestinal transplantation can be safely performed, with good outcomes, with a more minimalistic approach without the use of invasive monitoring, including PAC, TEE, and RIS.
OPTN/SRTR Intestine Report
The annual report on intestinal transplant was published in January 2017 and covers both intestine and intestineliver transplants. 8 In 2015, 99 patients were added to the intestine waitlist, and 97 were added to the intestine-liver waitlist. The report highlights a shift from primarily pediatric listings to primarily adult listings over the past 10 years. Short gut syndrome remains the most common reason for listing. Rate of transplantation was highest for adult intestine-liver transplant (151.5 per 100 waitlist years) and lowest for pediatric intestine transplant (18.8 per 100 waitlist years). Time to transplant was 6.7 months for adult intestine-liver transplants, 4.2 months for pediatric intestine-liver transplants, and 3.8 months for adult intestine transplants. In 2015, there were 70 intestine transplants and 71 intestine-liver transplants. Graft failure for intestine transplants was 19.3% at 6 months, 24.5% at 1 year, 42.4% at 3 years, 54.8% at 5 years, and 66.2% at 10 years. Graft failure for intestine-liver transplant was 17.6% at 6 months, 27% at 1 year, 33.8% at 3 years, 48.7% at 5 years, and 50.9% at 10 years. Patient survival rates were higher for intestine transplant than intestineliver transplant. Survival rates were highest for pediatric intestine (88.1% at 1 year, 74.6% at 5 years) and lowest for adult intestine-liver transplant (68.6% at 1 year, 35.7% at 5 years).
Kidney Transplantation
Cardiac Function/Intervention
Patients with end-stage renal disease (ESRD) who require transplantation are at significant risk for major adverse cardiac events. 9 In 2017, several studies were published that improve our understanding of the extent of this cardiac risk as well as the procedural risk of nontransplant surgery and cardiac intervention on the renal transplant population.
Risk of Adverse Cardiovascular Event Following Renal Transplantation.
In 2017, Seoane-Pillado et al 10 presented an observational study of more than 2000 renal transplant recipients (2029) spanning over 30 years (1981-2011) in Spain. These authors used a competing risk survival analysis to identify posttransplant cardiac events, including MI, invasive coronary artery therapy, cerebral vascular events, new-onset angina, CHF, arrhythmia, peripheral vascular disease, cardiovascular disease (CVD), and death and the characteristics associated with these events. The population was young (mean age = 47.0 years) and predominantly male (62%), and 16.5% had a pretransplant diagnosis of CVD. The mean follow-up to cardiovascular events was 3.5 years (±4.3 years), and with application of a competing risk methodology, it was found that the accumulated event incidence was 5.0%, 8.1%, and 11.9% within 1 year, 5 years, and 10 years, respectively. Pretransplant risk factors for such events were found to be gender (male), age of recipient (increased age increased risk), presence of preexisting CVD, pretransplant smoking, and posttransplant diabetes mellitus. 10 Lam et al 11 undertook a retrospective study of almost 5000 renal transplant recipients (4954) spanning 15 years (1994-2009) by analyzing health care databases from Ontario, Canada. Similar to Seoane-Pillado et al, 10 these authors examined posttransplant outcomes, including MI, coronary angioplasty, cerebral vascular accident, the need for coronary artery bypass surgery (CABG), and death but chose a 3-year posttransplant end point. They found that 445 recipients (9.0%) experienced a major adverse cardiovascular event (MACE) or death within the 3-year followup period without significant change in event rate over time. However, these authors found that when adjusting for age, sex, and comorbidities, the risk of MACE or death steadily declined over time (hazard ratio [HR] = 0.70; P = .009), whereas the median age for transplantation increased from 45 to 53 years (P < .001) with the proportion of recipients 65 years or older increasing from 5.7% to 17.1% (P < .001). Interestingly, the proportion of patients with pretransplant echocardiogram and coronary angiogram increased significantly across the study period (76% to 96%, P < .001, and 9.5% to 21%, P < .001, respectively). These authors found that the highest incidence of adverse events across all time periods was in the initial 0 to 3 months following transplantation (overall 7.96 events per 100 person-years) with this time to event holding stable over the study period.
11
Taken together, these 2 large retrospective studies of patients undergoing kidney transplantation in different continents offer additional insight into the risks of MACE and death in the highly susceptible population of patients undergoing renal transplantation. Particularly, the study by Lam et al 11 demonstrates that advances in preoperative testing/patient selection and management has allowed us to expand the transplant pool to a more elderly population while maintaining a similar risk of 3-year postoperative MACE and death.
Risk of Adverse Events in Surgical Interventions Following Renal
Transplantation. Taduru et al 12 used data from the National Inpatient Sample (2008 through 2014), an all-payer database of inpatient hospitalizations in the United States to determine the rates of acute kidney injury (AKI) and AKI requiring hemodialysis (HD) in patients who underwent percutaneous coronary intervention (PCI) or CABG following renal transplantation. These authors found 1871 patients who underwent PCI and 1878 who underwent CABG after propensity score matching for comorbid diseases and excluding patients with chronic kidney disease stage 5 or ESRD. The rates of AKI (22% vs 38%; OR = 2.20, 95% CI = 1.91-2.54, P < .001) and AKI requiring HD (1% vs 3%; OR = 2.50, 95% CI = 1.49-4.19, P = .001) were significantly higher among patients who underwent CABG as compared with those who underwent PCI. These authors note that the decision to perform PCI versus CABG is multifactorial, with the SYNTAX II formula providing validated mortality predictions to help guide the choice; this system does not take postprocedural renal function into account, something that could be of significant importance to the renal transplant population. 13 They further point out that compared with a previous study of patients who had not undergone renal transplantation prior to coronary intervention, their population had higher rates of AKI (30% vs 6%-20%) and AKI requiring HD (2% vs 0.2%-0.4%), 14 stressing the potential importance of including postprocedural renal function in the decision as to which type of coronary intervention to undergo.
Arhuidese et al 15 examined all renal transplant patients in the United States Renal Data System who underwent carotid endarterectomy (CEA) and carotid artery stenting (CAS) between 2006 and 2011 to assess the risk of perioperative stroke, MI, and death as well as long-term stroke and death. They identified 387 patients (84%) who underwent CEA and 75 (16%) who underwent CAS for asymptomatic carotid artery stenosis, with both groups being similar for demographic data and baseline comorbidities. The CEA groups had similar rates of perioperative stroke, MI, and death (4.7%, 4.4%, and 1.3%, respectively) compared to the CAS group (5.3%, 2.7%, and 4.0%, respectively). Stroke-free survival was comparable at 1 year (93% vs 92%) and at 4 years (84% vs 82%, P = .81), and overall patient survival was also comparable at 1 year (89% vs 88%) and at 4 years (53% vs 48%, P = .68). 15 Although the event rates and survival were found to be comparable between the intervention types, the overall rate of perioperative complications is above the 3% threshold for risk of perioperative stroke or death recommended by the Society of Vascular Surgery. 16 Following renal transplantation, patients maintain many of their preexisting comorbid diseases but with the addition of immunosuppression. The work by Taduru and Arhuidese in 2017 makes clear the importance of considering the history of renal transplantation when evaluating whether patients should have invasive procedures or surgery, and if so, what adverse events might be more prevalent and specific to these patients. These publications will help guide future work in this arena.
Outcomes
Perioperative Risk Mitigation. The Consensus On Managing Modifiable risk In Transplantation (COMMIT) group of experts in kidney and liver transplant work toward improving long-term patient and graft outcomes by providing recommendations for the management of modifiable risk factors. 17 In 2017, the group offered suggestions to improve immunosuppression adherence, exposure, and minimization of related adverse events such as infection and cancer. The group recommends mitigation of early ischemic injury and delayed graft function through maintenance of good hydration, ensuring hemodynamic stability, and avoidance of nephrotoxic agents, including nonsteroidal anti-inflammatory drugs, contrast agents, and certain antibiotics such as vancomycin and aminoglycosides.
Renal transplant patients are at elevated risk for MACE and death from cardiovascular events when compared with the general population, particularly within the first few months following transplantation.
11 MACE accounts for 18% to 30% of deaths in this population in the first 1 to 3 years posttransplant. 18 In addition to diabetes, obesity, hypertension, and dyslipidemia, cardiovascular risk factors in renal transplant patients include anemia, proteinuria, and graft rejection. 19, 20 COMMIT recommends standard lifestyle modification with diet, exercise, smoking and alcohol cessation, regular monitoring of glucose and glycated hemoglobin, managing hyperglycemia, and if necessary modifying immunosuppression to reduce hyperglycemia (ie, withdrawal of corticosteroids). They recommend calcium channel blockers for hypertension over RAS blockers (which are associated with graft dysfunction) and aggressive treatment of dyslipidemia with statins, with addition of fibrates and ezetimibe if necessary. 17 Frailty. The effect of frailty on outcomes in patients with end-stage liver disease has become a topic of significant interest over the past few years. [21] [22] [23] Frailty is a phenotypic marker of a patient's ability to overcome physiological stress, and in kidney transplant recipients, it has been associated with Delayed Graft Function (DGF), early hospital readmission, and mortality. [24] [25] [26] [27] McAdams-DeMarco et al 28 sought to characterize the association between frailty and length of stay (LOS) in kidney transplant recipients. In this prospective longitudinal study, baseline frailty immediately prior to kidney transplantation was assessed in 589 patients using the Fried frailty scoring system. 24 SRTR data on the LOS and comorbidities of 74 859 kidney transplant recipients was utilized to determine the normalized LOS by age and comorbid factors for the study participants. Frail kidney recipients demonstrated longer LOS [Relative Risk (RR) = 1.14; 95% CI = 1.02-1.28; P = .02] when matched for all other characteristics, including DGF, with nonfrail controls. Interestingly, these authors found that for every 1 week increase in LOS, there was a 1.08-fold increased risk of mortality but that this effect was pronounced in the nonfrail patients who demonstrated a 1.55-fold increased risk and absent in the frail population (HR = 0.97; CI = 0.79-1.19; P = .80). These authors concluded that there is an increased risk of mortality for frail patients owing to their lack of physiological reserve, and increased LOS does not increase this risk but instead may be a consequence of the frail state. However, in nonfrail patients with increased LOS, there is a clear increase in mortality risk related to the prolongation in hospital stay. Therefore, frail patients should be counseled on the risks of this physiological state prior to transplantation. 28 
OPTN/SRTR Kidney Report
The annual report on kidney transplant, published in January 2017, is the first report since implementation of the new kidney allocation system (KAS), and a second report highlighting specific effects of the KAS was published concurrently. 29, 30 KAS uses the Kidney Donor Profile Index (KDPI) to improve allocation, increases regional and national organ sharing, and prioritizes candidates waiting for multiorgan transplant, those with calculated panel-reactive antibodies above 98%, those with zero-HLA mismatch kidneys, pediatric patients, and those with prior living donors. Total waitlist patients decreased for the first time in a decade. Fewer new patients were listed, more patients were removed from the list because of medical conditions, and more patients were transplanted (55% of removed patients). The percentage of waitlist patients >65 years increased to 22% in 2015. Of note, fewer patients were willing to accept expanded criteria donor or KDPI >85% organs. This change in trend primarily took place with candidates >65 years old; this is thought provoking considering that this group of patients is less likely to undergo deceased donor transplantation. The supply-demand imbalance of waitlist candidates to available organs continues and is made worse by declining livingrelated kidney donations. KAS appears to have changed candidate transplantation rates. The number of candidates transplanted within 1 year of listing increased. The deceased donor transplant rate increased for candidates 18 to 49 years old, whereas the transplant rate for candidates older than 65 years decreased. The rate of transplantation for patients with diabetesrelated kidney failure is dropping, likely because of an increasing number of these patients on the list. Access to transplantation for minorities improved, with the proportion of Black and Hispanic recipients increasing. A total of 18 597 kidney transplants took place in 2015, 70% of which were from deceased donors. Graft and survival outcomes continue to improve, with decreasing 10-year graft failure rates for both deceased and living donor transplants. Deceased donor graft survival at 5 years was lowest for diabetic or hypertensive patients and those organs with KDPI >85%. Overall 5-year patient survival for deceased donors was poorer (86.8%) than for living donors (93.5%).
Liver Transplantation
Outcomes
High-Risk Recipients. One of the US transplantation policy changes has proven to be effective for the outcome of liver transplant (LT) patients. The Share 35 policy was implemented in June 2013 to improve equity in access to LT between patients with fulminant liver failure and those with cirrhosis and severe hepatic decompensation, with Model for End-Stage Liver Disease (MELD) score ≥35. Kwong et al 31 showed that Share 35 has had a positive impact on survival after transplantation in patients with MELD ≥35, without a reciprocal detriment to patients with lower acuity. In the study, all adult deceased donor LTs from 2010 to 2016 were analyzed. One-year patient survival before and after Share 35 was assessed. Of 34 975 adult LT recipients, 16 472 (47.1%) were transplanted after the implementation of Share 35, of whom 4599 (27.9%) had a MELD score ≥35. One-year patient survival improved from 83.9% to 88.4% after Share 35 (P < .01) for patients with MELD ≥35. There was no significant impact on survival of patients with MELD <35 (P = .69). Quality of donor organs, as measured by a donor risk index without the regional share component, improved for patients with MELD ≥35 (P < .01) and worsened for patients with lower MELD (P < .01). In multivariable Cox regression analysis, Share 35 was associated with improved 1-year patient survival (HR = 0.69; 95% CI = 0.60-0.80) in recipients with MELD ≥35. The authors determined that the improvement was in part a result of more favorable donor-recipient matching. 31 This policy change has had a positive impact on listing patients for the most urgent indication for LT: status 1. Approximately 5% of LTs annually are performed urgently with the status-1 designation. Wong et al 32 reported that LT for status 1 is decreasing, whereas survival remains excellent. They utilized the SRTR (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) to characterize 2352 adult patients who underwent 2408 status-1 LTs and compared them between Era-1 (2003-6/2009) and Era-2 (7/2009-2015) . Overall, there were fewer LTs performed with status-1 designation in Era-2 than Era-1 (1099 vs 1309). Although the number of urgent LTs was relatively constant with successive years, the proportion transplanted with status-1 designation decreased markedly over time. Era-2 patients were older (43.2 vs 41.7 years, P = .01) and less likely to be ABO incompatible (1.1% vs 2.4%, P = .01) or retransplants (77 vs 124, P = .03). The largest group was "ALF, nonspecified" (43.4%). There was no difference in proportion with drug-induced liver injury. Survival was increased in Era-2 in the overall cohort and for patients with autoimmune disease (P < .05) despite longer waiting times for this etiology (186 vs 149 days). Drug-induced liver injury or nonspecified ALF had shorter waiting times with 90% transplanted within 7 days. 32 At the same time, given the scarcity of the number of donors, the transplant team often must be mindful to avoid transplant futility. Michard et al 33 tried to address this difficult issue with a single-center retrospective study and suggested that low serum lactate level and the absence of acute respiratory distress syndrome (ARDS) could be useful criteria in selecting those patients in the intensive care unit (ICU) who could be eligible for liver transplant. A total of 84 patients (29 with acute liver failure and 55 with acute-on-chronic liver failure) received LT while they were hospitalized in the ICU. Their mean laboratory MELD score was 41, and their mean sequential organ failure assessment score was 15 the day before transplant. The overall 1-year survival rate was 66%. In multivariate analysis, pretransplant lactate level and ARDS were the only 2 independent factors associated with posttransplant mortality. The absence of ARDS and a pretransplant lactate level <5 mmol/L led to the identification of a subgroup of ICU patients with a good 1-year posttransplant survival (>80%). 
Cardiovascular and Pulmonary Issues
Cardiovascular Risk Factors. Cardiovascular complications are considered the leading cause of non-graft-related morbidity and mortality early after LT. However, some experts rightly critique that the true incidence of adverse cardiovascular outcomes post-LT remains unknown, in large part because of a lack of consensus regarding uniform definitions for such outcomes. 35 A diverse working group representing multiple relevant disciplines (hepatology, transplant surgery, critical care/anesthesiology, and cardiology) from a variety of institutions were assembled and addressed this issue. 36 This special article is a work product of the American Society of Transplantation's Liver and Intestinal, and Thoracic and Critical Care Communities of Practice and has been endorsed by the American Society of Transplantation. They discussed the key points and practice-based recommendations for the diagnosis and management of LT patients with coronary artery disease, heart failure and cardiomyopathy, portopulmonary hypertension (PoPH), cardiac dysrhythmias, valvular heart disease, or congenital heart disease. Finally, the role of combined heart liver transplantation was discussed. It is one of the most highly recommended readings for perioperative transplant physicians.
Given the lack of preoperative risk assessment tools that allow physicians to estimate the risk for CVD events following LT, VanWagner et al 36 [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] . 37 Major CVD complications occurred in 329 (32.1%) recipients. Variables selected for inclusion in the model were preoperative recipient age, sex, race, employment status, education status, history of hepatocellular carcinoma, diabetes, heart failure, atrial fibrillation, pulmonary or systemic hypertension, and respiratory failure. The discriminative performance of the score (c-statistic = 0.78, bias-corrected c-statistic = 0.77) was superior to other published risk models for postoperative CVD morbidity and mortality, and it had appropriate calibration (HosmerLemeshow P = .33). 37 Cardiac troponin has been reported to provide prognostic information of all-cause death during the perioperative period among patients undergoing noncardiac surgery. 38 Park et al 39 demonstrated that elevation of preoperative high-sensitivity cardiac troponin I (hs-cTnI) level was associated with 1-year mortality and 30-day mortality for patients who underwent LT. From January 2011 to May 2016, preoperative hs-cTnI level was measured in 487 consecutive patients scheduled for LT. Patients with elevated preoperative hs-cTnI were compared with those who had a normal level. The primary outcome was all-cause death in the follow-up period of 30 days to 1 year after surgery. Of the 487 patients, 58 (11.9%) had elevated preoperative hs-cTnI and 429 (88.1%) had normal preoperative hs-cTnI. In multivariate analysis, the rate of 1-year mortality and 30-day mortality were higher in the elevated preoperative hs-cTnI group (HR = 3.69, 95% CI = 1.83-7.42, P < .001, and HR = 6.61, 95% CI = 1.91-22.82, P = .003, respectively). After adjustment with inverse probability weighting, the incidence of 1-year mortality and 30-day mortality were higher in the elevated hs-cTnI group (HR = 4.66, 95% CI = 3.56-6.1, P < .001, and HR = 10.31, 95% CI = 6.39-16.66, P < .001, respectively). 39 Diastolic and autonomic cardiac dysfunction is common and plays a key role in the prognosis of patients with end-stage liver disease. Using a novel 2-dimensional speckle tracking echocardiography, Jansen et al 40 reported for the first time the role of myocardial contractility and its prognostic value for the patients on the list for LT. A total of 168 patients with cirrhosis (training cohort, 111; validation cohort [VC], 57) awaiting LT in 2 centers were included in this retrospective study. In all, 51 patients from the training cohort and all patients from the VC were transplanted, and 36 patients of the training and 38 of the VC were alive at the end of follow-up; 21 nontransplanted patients died. Contractility of the left ventricle (LV) increased with severity of the Child-Pugh score. Higher LV contractility in the training cohort patients, especially in those with Child-Pugh C, was an independent predictor of reduced transplant-free survival. Competing risk analysis demonstrated that increased contractility is associated with earlier LT, which was confirmed in the VC. Importantly, LV myocardial contractility had no impact on survival of patients not receiving LT or on post-LT survival. They concluded that increased myocardial contractility in decompensated patients identifies patients who require LT earlier but without increased post-LT mortality. 40 Portopulmonary Hypertension. Management of PoPH remains a clinical challenge in the pre-LT and post-LT setting. 41 A French multicenter retrospective study was performed to identify factors associated with normalization of pulmonary hypertension after LT. 42 A total of 28 (0.8%) patients presented with PoPH for LT among 3315 LTs in 8 centers between 2008 and 2016. Among them, 5 patients were not included in the analysis for the following reasons: diagnosis of PAH was only confirmed after the LT procedure (n = 3); diagnosis of PoPH was performed on echocardiography without right heart catheterization (RHC) (n = 1); LT was cancelled because of severe PoPH diagnosis in the operating room (n = 1). The remaining 23 PoPH patients were analyzed with a median follow-up of 47 (0-94) months. Two (8.7%) patients died in the immediate posttransplant period from right heart failure. With appropriate vasoactive medical treatment and LT, pulmonary arterial pressure (PAP) was normalized in 14 patients (60.8%). In univariate analysis, the use of 2 vasodilator medications was identified as a contributing factor for pulmonary arterial hypertension normalization after LT. 42 Transplant anesthesiologists may unexpectedly encounter pulmonary hypertension after induction of general anesthesia of LT recipients because the mean PAP (mPAP) of 35 mm Hg or greater can occur in the setting of normal pulmonary vascular resistance from a high flow state and/ or increased pulmonary venous volume. DeMartino et al 43 described the frequency of patients with mPAP of 35 mm Hg or greater at LT and correlated their clinical outcomes with hemodynamic characteristics. In 300 LT recipients, pulmonary hypertension was documented in 117 (39%). Five patients were receiving ongoing treatment for PoPH at the time of transplant. A mPAP of 35 mm Hg or greater was seen in 31 of 300 patients (10.3%; median = 38 mm Hg; range = 35-46 mm Hg). No intraoperative deaths occurred. Transplant hospitalization mortality was 0% for those with mPAP of 35 mm Hg or greater (vs 2.2% if mPAP <35 mm Hg, P = 1.0). One-year mortality was similar for patients with and without mPAP of 35 mm Hg or greater (3.2% vs 6.0%, P = 1.0). No deaths were associated with right heart failure. They concluded that transplant hospitalization and 1-year posttransplant outcomes were not adversely affected when associated with a high flow state and/or increased volume. 43 Intracardiac and Pulmonary Thromboembolism. Intracardiac and pulmonary thromboembolism (ICPTE) often leads to significant patient mortality and morbidity during LT. Fukazawa et al 44 analyzed 41 324 adult LT recipients in the Standard Transplant Analysis and Research database who underwent LT between 2002 and 2013. They identified postoperative 24-hour mortality of 547 (1.3%) and 2484 (6.0%) within the subsequent 30 days. Uncontrolled hemorrhage (57 patients, 0.14%), ICPTE (54 patients, 0.13%), or primary graft failure (49 patients, 0.12%) contributed to the 24-hour mortality. They further found that recipients' prior history of pulmonary embolism, portal vein thrombosis, functional status (Karnofsky) score <20, preoperative ventilator support, diabetes mellitus, and Asian ethnicity were significant independent hazard factors for ICPTE. These risk factors were expressed as an index to calculate the overall hazard of a devastating ICPTE (c-statistics, 0.70; P < .001). 44 Monitoring. Perioperative physicians are interested in finding less invasive perioperative monitoring devices. Lee et al 45 
Renal Issue: Intraoperative Renal Protection
Renal Replacement Therapy. LT in patients with high acuity of illness is frequently complicated by profound increases in the degree of fluid shifts, electrolyte disturbances, prolonged acidosis, and hemodynamic instability. Intraoperative renal replacement therapy (RRT) is an adjunctive therapy that addresses these challenges. However, the quantifiable impact on short-and long-term outcomes post-LT is unclear. Zimmerman et al 46 performed a single-center retrospective analysis on 96 adult patients who underwent LT from 2012 to 2016. Three groups were identified: (1) group I, 30 patients with pre-LT renal dysfunction who underwent intraoperative RRT; (2) group II, 9 patients with pre-LT renal dysfunction who did not receive intraoperative RRT; and (3) group III, 57 patients with LT without evidence of pretransplant renal dysfunction. At the 17.7-month follow-up, there was no difference in survival among the study groups. Laboratory MELD score at the time of LT was significantly higher in both groups with renal dysfunction (group I, MELD = 43; group II, MELD = 39) than in group III (MELD = 18). The 12-month post-LT patient survival was comparable at 78% (I) versus 100% (II) versus 88% (III); P = . 19 . Although the number of cases was small, they concluded that intraoperative RRT is a safe adjunctive therapy during LT of critically ill patients with renal dysfunction.
Terlipressin. Terlipressin (triglycyl-lysine vasopressin) is a long-acting vasopressin analog that selectively causes splanchnic and extra renal vasoconstriction, which helps reduce splanchnic blood flow and portal pressure. In 2013, a randomized control trial from Egypt found that a continuous infusion of terlipressin starting during the LT and running for 3 days had a beneficial effect on hemodynamics and postprocedure renal function in living donor LT. 47 Kandil et al 48 at Menoufia University in Egypt performed another double-blinded prospective randomized controlled trial on 50 adult living donor LT recipients with low MELD score (between 12 and 20) , where the study group (n = 25) received continuous infusion of terlipressin (1-4 µg/kg/h) for 5 days, whereas the control group (CG; n = 25) received a placebo infusion of crystalloids. Intraoperative transesophageal Doppler echocardiography was used to measure peak portal vein blood flow velocity (PPV) and hepatic artery resistive index (HARI). Renal function, including plasma NGAL (pNGAL), was measured at baseline and at 2 and 24 hours postreperfusion. Postoperative AKI incidence and pNGAL concentration were comparable (P > .05) between the terlipressin and CGs (44% vs 48% and 112.5 ± 9 vs 93.1 ± 8 ng/mL), respectively. The 3 pNGAL readings were comparable (P > .05) between AKI (n = 23) and non-AKI developers (n = 27). The PPV and HARI were not affected by terlipressin at any stage (P > .05).
They concluded that terlipressin was not effective to prevent AKI for patients undergoing LT. 48 Venovenous Bypass. Xia et al demonstrated that utilization of intraoperative venovenous bypass (VVB) was associated with a significantly lower incidence of posttransplant AKI in patients with compromised pretransplant renal function. 49 In the retrospective study of 1037 primary LTs performed between 2004 and 2014, they identified 247 (23.8%) LT patients with VVB. A propensity matching was performed to create 221 matches (1:1 ratio between VVB and non-VVB). Matched patients were further divided according to a predicted probability AKI model using preoperative creatinine (Cr), VVB, and intraoperative variables into 2 subgroups: normal and compromised pretransplant renal function. In patients with compromised pretransplant renal function (Cr ≥1.2 mg/dL), the incidence of AKI was significantly lower in the VVB group compared with the non-VVB group (37.2% vs 50.8%; P = .033). VVB was an independent risk mitigating factor for AKI (OR = 0.1; 95% CI = 0.1-0.4; P = .001). Renal replacement in 30 days and 1-year recipient mortality were not significantly different between the 2 groups. The incidence of posttransplant AKI was not significantly different between the 2 groups in patients with normal pretransplant renal function (Cr < 1.2 mg/dL). 49 Of note, the editorial accompanying the article discussed a very interesting insight on retrospective studies. 50 Avoidance of Old RBC Transfusion. Transfusion of older RBCs has been implicated in poor outcomes in trauma, cardiac surgery, and critically ill patients. Wang et al 51 found that transfusion of older RBCs significantly increased the risk of postoperative AKI in LT recipients. They retrospectively examined consecutive adult LT patients with donation after cardiac death grafts from 2011 to 2015. In 137 patients, 74 patients received RBCs that had been stored for 14 days or less (newer blood), and 63 patients received any RBCs that had been stored for more than 14 days (older blood). The minimum and maximum storage times of the transfused RBCs were 3 and 34 days, respectively. The median duration of RBCs storage was 13 days. The newer blood group and the older blood group received 12 (7-24) units/patient (1 unit red cells = 200 mL red cells) and 16 (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) units/patient of RBCs, respectively. Postoperative AKI occurred in 65.1% of patients in the older blood group and 40.5% of patients in the newer blood group (P < .01). The incidence of severe AKI after LT was significantly higher, and the duration of ICU stay was significantly longer in the older blood group. Transfusion of older blood was independently associated with post-LT AKI (OR = 2.47; 95% CI = 1.13-5.41; P = .024) and severe AKI (OR = 5.88; 95% CI = 2.06-16.80; P = .001). After adjustment by the inverse probability of treatment weighting analysis, patients in the older blood group still had significantly higher incidences of post-LT AKI (OR = 2.13; 95% CI = 1.07-4.22; P = .030) and severe AKI (OR = 3.34; 95% CI = 1.47-7.60; P = .003) than those in the newer blood group. . A probability cutoff threshold of 0.25 was found to misclassify only 4 of 100 patients as unlikely to experience MT, with the majority such misclassifications within 4 units of the working definition for MT. For this threshold, a preoperative blood ordering schedule that allocated 6 units of pRBCs for those unlikely to experience MT and 15 for those who were likely to experience MT would prevent unnecessary cross-matching of 338 units/100 transplants. 52 Tranexamic Acid. To reappraise the efficacy of tranexamic acid (TXA) in reducing blood loss and transfusion requirements during LT and its potential risk of thromboembolic complications, Badenoch et al 53 conducted a retrospective propensity matching study on 1799 consecutive LT recipients between 2002 and 2015. Exposure to TXA was defined as a total TXA dose >10 mg/kg for 50% of the operative duration. After propensity matching, 367 unique pairs were prepared. In the matched pairs, patients exposed to TXA received less pRBCs (3 [0, 6] vs 4 [1, 7] , P = .003) and frozen plasma (6 [2, 10] vs 6 [2, 12] , P = .032) transfusions. There were no differences in thromboembolic events between the groups (22 [6.0%] vs 36 [9.8%] ). In this single retrospective study, TXA appears to be effective in reducing the amount of blood transfusion without increasing the risk of thromboembolic events across a wide range of LT recipients.
Prothrombin Complex Concentrates. Plasma transfusion remains the mainstay hemostatic therapy during LT despite a concern for its large volume requirement. Given the high concentration of factors in a low volume of administration, prothrombin complex concentrates (PCCs) could be an attractive alternative for plasma transfusion during LT. An in vitro study using thrombin generation assay demonstrated that reduced thrombin generation in LT can be more effectively restored by using PCC rather than plasma. 54 The required doses of PCC for LT patients seem to be lower than warfarin reversal because of slow thrombin inhibition. 54 The efficacy of PCC, however, has not been well studied in LT. Colavecchia et al 55 reported a propensity score-matched comparison study on 212 consecutive LT patients between 2013 and 2016. Of note, the use and administration of factor concentrates were not according to any protocol at the institution, and providers used either allogeneic blood products or factor concentrates according to their clinical judgment. There were 39 patients who received PCC. Using a propensity score matching at a 2 to 1 ratio, 78 patients who were not exposed to PCC were identified. They observed that 84.6% of PCC-exposed patients also received fibrinogen concentrate, whereas only 2% of non-PCC-exposed patients received fibrinogen concentrate. The mean administered dosage of PCC was 902 ± 589 units, and the mean dose of fibrinogen concentrate was 1679 ± 1107 mg. There was no statistical difference in the number of RBC, fresh frozen plasma, or cryoprecipitate doses transfused during surgery in the PCC and fibrinogen concentrate exposed group versus the CG (mean ± SD RBC units: 12.4 ± 8.0 units vs 9.7 ± 5.6 units, respectively, P = .058; fresh frozen plasma units: 10.5 ± 8.1 vs 8.3 ± 5.2 units, respectively, P = .119; cryoprecipitate doses: 2.6 ± 6.4 vs 2.5 ± 5.4 doses, respectively, P = .642). Patients who were exposed to PCC and fibrinogen concentrate required significantly more platelet transfusions during surgery (3.1 ± 1.8 vs 2.2 ± 1.5 units; P = .005). ) of pretransplant ME level with patient and graft survival over 5 years after transplant were quantified by multivariate Cox regression, including adjustment for recipient, donor, and transplant factors as well as propensity adjustment for opioid use. Overall, 9.3% of recipients filled opioids on the waiting list. Compared with no use, level 3 (aHR 1.06 1.28 1.55 ) and 4 (aHR 1.16 1.52 1.98 ) opioid use during listing were associated with increased mortality over 5 years after transplant. These associations were driven by risk after the first transplant anniversary, such that mortality >1 to 5 years increased in a graded manner with higher use on the waiting list (level 2, aHR, 1.00 1.27 1.62 ; level 3, aHR, 1.08 1.38 1.77 ; level 4, aHR, 1.49 2.01 2.72 ). Similar patterns occurred for graft failure. Of recipients with the highest level of opioids on the waiting list, 65% had level 3 or 4 use in the first year after transplant, including 55% with use at these levels from day 90 to 365 after transplant. Opioid use in the first year after transplant also bore graded associations with subsequent death and graft loss >1 to 5 years after transplant. They concluded that opioid use history may be relevant in assessing and providing care to LT candidates. 58 This issue has been further examined by Fleming et al, 59 who conducted a national survey to determine the practices and policies pertaining to opioid and opioid substitution therapy (OST) use in the selection of LT candidates. 
Economic Issues
Hospitalization. Facing a potential for future bundled payments for LT in the United States, understanding inpatient needs in the early post-LT period could be used for payer negotiations that include reimbursement for early rehospitalizations after LT. The identification of patients at risk for poor outcomes despite life-saving LT is important for proper candidate selection in extreme circumstances. Bittermann et al 60 conducted a study to comprehensively evaluate the association between pre-LT and post-LT health care utilization in a large multicenter cohort. This was a retrospective study of 34 402 adult LTs between 2002 and 2013 using Vizient inpatient claims data linked to the United Network for Organ Sharing (UNOS) database. Of those patients alive at LT discharge, 24.7% spent ≥30 days hospitalized during the first year. Hospitalization in the 90 days pre-LT was inversely associated with days alive and out of the hospital (DAOH; β = −3.4 DAOH per week hospitalized pre-LT; P = .002). Centers with >30% of their LT recipients hospitalized ≥30 days in the first year following LT were typically smaller volume and/or transplanting higher-risk recipients (MELD score ≥35, inpatient or ventilated pre-LT). Pre-LT hospitalization predicts 1-year post-LT hospitalization independent of MELD score at the patient level, whereas center-specific post-LT health care utilization is associated with certain center behaviors and selection practices. They suggested that DAOH as a post-LT metric could provide a novel framework with which to educate patients about expectations after LT.
As transplant recipients with prolonged hospital stays could consume the finances of transplant programs and exhaust national health care resources, there is a pressing need for an index that accurately predicts posttransplant LOS. Rana Delirium. Delirium is increasingly recognized as a common and important postoperative complication that significantly hinders surgical recovery. Two studies identified post-LT delirium as a common occurrence among LT patients and associated its presence with increased complications and length of hospital stay. In a retrospective study of 144 LT patients, Bhattacharya et al 62 found that post-LT delirium occurred in 25% of patients with an average duration of 4.6 days. Patients who developed delirium were older (P = .007) and had higher preoperative MELD score (P = .019) and longer pretransplant hospital LOS (P = .003). Patients with delirium were also more likely to have alcohol ingestion as an etiology of the liver failure (P = .033). Delirious patients had a significantly longer postoperative hospital LOS (P = .001) and ICU (P = .001) LOS. Delirium was also associated with an increased frequency of hospital-acquired infections, including urinary tract infections (P = .005) and pneumonias (P = .001). 62 Beckmann et al 63 performed a prospective observational study on 42 LT patients (69% male, mean age = 55 years with a median MELD score of 15 [interquartile range = 8-26] ). Postoperative delirium was assessed 3 times daily until 24 days post-LT, with the Intensive Care Delirium Screening Checklist in the ICU and the Delirium Observation Screening Scale in the ward. The incidence of post-LT delirium was 45.2%, with a median duration of 5 days. Patients with post-LT delirium had longer ICU (median 8 vs 2 days, P = .000) and hospital stays (median 32 vs 14 days, P = .000). 63 Care Coordination. Avoidance of care fragmentation is important to reduce medical resource waste and medical errors. Kothari et al 64 found an adverse impact of fragmented readmissions within the first year after LT on the risk of both 30-day mortality and subsequent readmission after a readmission in the first year after LT. 64 The 
Transplant Anesthesia Education
Anesthetic management of LT is complex, but anesthesiology providers receive relatively uneven LT training and exposure because of unequal distributions of LT performed at different centers. To teach best practices for anesthetic management of a standard LT, Katz et al 65 introduced a unique "serious game" modality called the LT Trainer: an interactive application created for imparting knowledge or skills while leveraging the self-motivating elements of video games. In all, 44 anesthesiology residents on the LT rotation were randomized to either the gaming group (GG) or the CG prior to their introductory simulation. Both groups were given access to the same educational materials and literature during their rotation, but the GG also had access to the LT Trainer. Although both groups experienced an increase in score relative to baseline that was statistically significant at every stage, the improvements in scores were greater for the GG participants than the CG participants. Overall score improvement between the GG and CG (mean [SD]) was statistically significant (GG, 7.95 [3.65] ; CG, 4.8 [4.48] ; P = .02), as were scores for preoperative assessment (GG, 2.67 [2.09]; CG, 1.17 [1.43] ; P = .01) and the anhepatic phase (GG, 1.62 [1.01]; CG, 0.75 [1.28] ; P = .02). Of the residents with game access, 81% were "very satisfied" or "satisfied" with the game overall. They concluded that adding a serious game to an existing educational curriculum for LT anesthesia resulted in significant learning gains for rotating anesthesia residents. 65 
OPTN/SRTR Liver Report
The OPTN/SRTR 2015 Annual Data Report reported the largest number of adult LTs performed to date (7127). 66 The increase was attributable to increases in both more deceased donor (n = 6768) and more living donor (n = 359) transplants. The increase led to reductions in median waiting time, in waitlist mortality for all MELD categories, and in the number of candidates on the waiting list at the end of the year. As of December 31, 2015, 14 046 candidates were registered on the waiting list, including 11 699 in active status. Despite the increase in the number of LTs performed, the organ shortage remained severe. During 2015, 1673 patients died without undergoing transplant and another 1227 were removed from the waiting list because they were too sick to undergo LT. Another notable trend in 2015 was the reduction in waitlist registrations and transplants in candidates with a diagnosis of hepatitis C virus, likely attributable to the new highly effective antiviral therapies. In contrast, the numbers of candidates and recipients with other/unknown diagnoses increased, likely reflecting the increasing burden of fatty liver disease. LT outcomes continued to improve, with further reductions in the incidence of acute rejection and graft failure. Recipients of deceased donor livers in 2005 had a 10-year survival rate of 53%. As of June 30, 2015, nearly 75 000 adults were living with a functioning liver graft. 66 
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